We Claim

1. An antagonist to angiopoietin like 4 protein (ANGPTL4) that reduces cell proliferation and reduces the level of Reactive Oxygen Species in a cell, wherein the antagonist comprises an interfering RNA sequence as set out in SEQ ID NO. 6 or SEQ ID NO. 7.

2. A method of reducing cell proliferation and reducing the level of Reactive Oxygen Species in an *in vitro* cell, which comprises the step of: (a) contacting proliferating cell with an antagonist to angiopoietin like 4 protein (ANGPTL4) wherein the antagonist comprises an interfering RNA sequence as set out in SEQ ID NO. 6 or SEQ ID NO. 7.

3. An antagonist to angiopoietin like 4 protein (ANGPTL4) for use in the treatment of a cancer wherein the antagonist comprises an interfering RNA sequence as set out in SEQ ID NO. 6 or SEQ ID NO. 7 that reduces cell proliferation and reduces the level of Reactive Oxygen Species in a cell.

4. A composition comprising a therapeutically effective amount of an antagonist to angiopoietin like 4 protein (ANGPTL4) wherein the antagonist comprises an interfering RNA sequence as set out in SEQ ID NO. 6 or SEQ ID NO. 7 that reduces cell proliferation and reduces the level of Reactive Oxygen Species in a cell.

5. The antagonist or composition of any one of claims 1, 3 or 4 wherein the antagonist is for use in suppression of tumor growth.

6. The antagonist or composition of any one of claims 1, 3 or 4 for use in the treatment of metastasis.